Personal profile
Headline
ASSOCIATE PROFESSOR | Medicine, Hematology and Medical Oncology
Biography
Dr Chari is an Associate Professor of Medicine, the Director of Clinical Research in the Multiple Myeloma Program, and the Associate Director of Clinical Research, Mt Sinai Cancer Clinical Trials Office. Clinical Interests: Plasma cell disorders, including multiple myeloma, AL amyloidosis, POEMS syndrome, plasmacytoma, and monoclonal gammopathies of uncertain significance (MGUS). Dr Chari has published extensively on these topics and has been invited to speak regionally, nationally, and also internationally. Research Interests: Dr Chari’s research interests include the development of novel chemotherapy regimens, including phase 1 and 2 studies. He is principal investigator (PI) of several investigator-initiated trials as well as the national and international PI of several industry sponsored studies. As the Director of Clinical Research in the Multiple Myeloma Program, he oversees a program renowned nationally not only for high volume patient accruals but also rigorous quality assurance. The program has played a pivotal role in the approval of each of the 5 most recent drugs to be approved by the FDA for the treatment of multiple myeloma.
Fingerprint
Dive into the research topics where Ajai Chari is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Long-term remission after cilta-cel in multiple myeloma is linked to diverse T cells and low myeloid suppression
Vieira dos Santos, J., Melnekoff, D. T., Aleman, A., Mouhieddine, T. H., Montes de Oca, R., Wang, F., Rajeeve, S., Bhalla, S., Van Oekelen, O., Upadhyaya, B., Ghodke-Puranik, Y., Leshchenko, V., Kim-Schulze, S., Rahman, A., Afik, S., Lewinsky, H., Plaks, V., Thibaud, S., Cho, H. J. & Richter, J. & 9 others, , 10 Feb 2026, In: Blood advances. 10, 3, p. 604-607 4 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Author Correction: Mobilization strategies with and without plerixafor for autologous stem cell transplant in patients with multiple myeloma (Bone Marrow Transplantation, (2024), 59, 10, (1440-1448), 10.1038/s41409-024-02385-1)
Avigan, Z. M., Arinsburg, S., Pan, D., Mark, T., Fausel, C., Bubalo, J., Milkovich, G., Moshier, E., Fu, W., Chari, A. & Richter, J., Jan 2025, In: Bone Marrow Transplantation. 60, 1, p. 115 1 p.Research output: Contribution to journal › Comment/debate
Open Access -
Characterization and Management of Cytokine Release Syndrome From the MonumenTAL-1 Study of Talquetamab in Patients With Relapsed/Refractory Multiple Myeloma
van de Donk, N. W. C. J., Chari, A., Martin, T., Krishnan, A., Rasche, L., Ye, J. C., Popat, R., Lipe, B., Rodriguez, C., Schinke, C., Skerget, S., Vishwamitra, D., Verona, R., Gong, J., Singh, I., Campagna, M., Masterson, T., Hilder, B., Tolbert, J. & Renaud, T. & 3 others, , Oct 2025, In: Cancer Medicine. 14, 19, e71276.Research output: Contribution to journal › Article › peer-review
Open Access -
Correction to: Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes (Nature Genetics, (2024), 56, 9, (1878-1889), 10.1038/s41588-024-01853-0)
The MMRF CoMMpass Network, Jul 2025, In: Nature Genetics. 57, 7, p. 1789 1 p.Research output: Contribution to journal › Comment/debate
Open Access -
Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes
Facon, T., Moreau, P., Weisel, K., Goldschmidt, H., Usmani, S. Z., Chari, A., Plesner, T., Orlowski, R. Z., Bahlis, N., Basu, S., Hulin, C., Quach, H., O’Dwyer, M., Perrot, A., Jacquet, C., Venner, C. P., Raje, N., Tiab, M., Macro, M. & Frenzel, L. & 8 others, , Apr 2025, In: Leukemia. 39, 4, p. 942-950 9 p., 53.Research output: Contribution to journal › Article › peer-review
Open Access28 Scopus citations
Press/Media
-
The Intricacies of Bispecific Antibodies in Multiple Myeloma
7/12/25
1 item of Media coverage
Press/Media
-
AI-Powered Scout Platform Could Enhance Oncology Decision-Making With Data- and Expert-Driven Insights
1/11/25
1 item of Media coverage
Press/Media
-
No transplant, no problem: Redefining first-line myeloma care with anti-CD38 therapies
1/10/25
1 item of Media coverage
Press/Media
-
Case 3: Optimal Sequencing of T-Cell–Redirected Therapies
12/08/25
1 item of Media coverage
Press/Media